アジア太平洋地域の線維性疾患治療市場
Market Size in USD Billion
CAGR : %
予測期間 |
2024 –2030 |
市場規模(基準年) |
|
Market Size (Forecast Year) |
|
CAGR |
|
主要市場プレーヤー |
>アジア太平洋地域の線維性疾患治療市場、治療(薬物療法、臓器移植、酸素療法、その他)、用途(特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他)、エンドユーザー(病院、専門クリニック、学術研究機関、その他)、流通チャネル(病院薬局、小売薬局、その他)別 - 2030年までの業界動向と予測。
アジア太平洋地域の線維性疾患治療市場の分析と洞察
アジア太平洋地域の線維性疾患治療市場は、線維性疾患の罹患率の上昇、喫煙者数の増加、線維性疾患の治療における技術的進歩などの要因によって牽引され、市場の成長につながっています。現在、先進国と新興国全体で医療費が増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性を生み出すことが期待されています。
アジア太平洋の線維性疾患治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームは、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間中の市場の需要を推進した主な原動力です。
アジア太平洋地域の線維性疾患治療市場は、疾患の進行を抑えることを目標としており、支援的である。データブリッジ・マーケット・リサーチは、アジア太平洋地域の線維性疾患治療市場は、2022年から2030年の予測期間中に6.0%のCAGRで成長すると分析している。
レポートメトリック |
詳細 |
予測期間 |
2023年から2030年 |
基準年 |
2021 |
歴史的な年 |
2020 (2015~2020年にカスタマイズ可能) |
定量単位 |
売上高は1000米ドル、価格は米ドル、数量は個数 |
対象セグメント |
治療(薬物療法、臓器移植、酸素療法、その他)、用途(特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他)、エンドユーザー(病院、専門クリニック、学術研究機関、その他)、流通チャネル(病院薬局、小売薬局、その他) |
対象国 |
日本、中国、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、台湾、その他のアジア太平洋諸国 |
対象となる市場プレーヤー |
Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH among others |
Market Definition
The term fibrosis describes the development of fibrous connective tissue as a reparative response to injury or damage. Fibrosis may refer to the connective tissue deposition that occurs as part of normal healing or to the excess tissue deposition that occurs as a pathological process. Diseases characterized by uncontrolled, progressive fibrosis include Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), and Systemic Sclerosis (SSc).
Fibrosis is a group of serious organ/tissue diseases that affect the tissue system. Fibrosis scars and thickens the tissue. It impacts the connecting tissue, for instance, in the lung and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time. Hard, stiff lung tissues don't expand as well as they should, making it harder to breathe. Pulmonary fibrosis may cause shortness of breath when you do routine tasks that never seemed tiring before.
Asia-Pacific Fibrotic Diseases Treatment Market Dynamics
Drivers
- Rising prevalence of fibrotic diseases
Due to various risk factors such as aging, obesity, high blood pressure (hypertension), or family history of fibrotic disease, patients with fibrotic diseases are rising globally and becoming a significant socio-economic issue. Thus, the rising number of patients with fibrotic diseases increases the demand for treatment, which act as a driver in the fibrotic diseases treatment market.
- Increase in the number of people smoking cigarettes
Cigarette smoking is one of the most recognized risk factors for the development of Idiopathic Pulmonary Fibrosis (IPF). Furthermore, recent work suggests that smoking may have a detrimental effect on the survival of patients with IPF. The mechanism by which smoking may contribute to the pathogenesis of IPF is largely unknown. However, accumulating evidence suggests that increased oxidative stress might promote disease progression in IPF patients who are current and former smokers.
Thus cigarette smoke contains particulate matter as well as numerous chemicals, including highly toxic RONS, which increases the swelling inside the body and hence lead to various diseases, including pulmonary fibrosis, cancer among others, which is expected to drive the growth of fibrotic diseases treatment market.
- Technological advancement in the treatment of fibrosis diseases
IPF is characterized by the progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2–4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant, or trial recruitment. Significant recent advances in the field have led to two novel anti-fibrotic agents, pirfenidone and nintedanib, which have been shown to significantly slow disease progression in IPF.
Thus increasing technological advancements for the detection and treatment of fibrotic diseases is expected to drive the growth of the fibrotic diseases treatment market.
Opportunities
- Rising research and development activities
The research and development activities have significantly opened various ways for the treatment of several diseases. The emerging technological advancements, along with the appropriate research, lead to the formation of several drugs for the treatment of diseases. Most people associate a company's research and development function with the invention of new products. While inventions are important, the development of existing products is of equal significance as consumer preferences are continually changing.
Thus, rising research and development activities for fibrotic disease medications and treatment are expected to act as opportunities for the growth of the fibrotic diseases treatment market.
- Development of new and more effective therapies for fibrotic diseases
There are very few treatment options available for fibrotic diseases. These include medication which includes pirfenidone and nintedanib, oxygen therapy, organ transplantation, and pulmonary rehabilitation.
Hence the rising development of new and more effective therapies for fibrotic diseases will provide new opportunities in the fibrotic diseases treatment market.
Restraints/Challenges
- High cost of medication and treatments
Fibrotic disease treatments have become increasingly expensive due to the growing number of patients suffering from fibrosis and the risen prices of medical devices and medications. The modern technological devices used in fibrosis treatment are also playing a significant role in the high prices of treatments, and high accuracy, providing a definitive diagnosis for Idiopathic Pulmonary Fibrosis (IPF). Therefore, the high cost of medications and treatment procedures for fibrotic disease is hampering the market's growth.
Hence, the high cost associated with the medication and treatment of fibrotic disease is expected to restrict the growth of the fibrotic diseases treatment market.
- Lack of effective biomarkers and diagnostic tools for early detection and monitoring of fibrotic diseases
Biomarkers can be measurements of physiological and pathological processes or drug effects. For instance, they can distinguish the disease from health or other similar diseases (a diagnostic); they can predict mortality, exacerbation, and disease progression (a prognostic); and as well as predict a response to therapy (a theranostic).
Therefore, the limited availability of chest imaging in developing countries is considered a chief obstacle to diagnosis since high-resolution computed tomography of the chest is the key diagnostic test for Idiopathic Pulmonary Fibrosis (IPF). Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries, which is expected to restrain the growth of the fibrotic diseases treatment market.
- The complex and multifactorial nature of fibrotic diseases.
Although complex fibrotic disorders often cluster in families, they do not have a clear-cut pattern of inheritance. It may be difficult to identify the role of genetics in these disorders, particularly because families often also share environments and may have similar lifestyles. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified.
Hence the complex and multifactorial nature of fibrotic disease is expected to challenge the fibrotic diseases treatment market.
Recent Development
- In May 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and ArisGlobal, the Asia-Pacific market leader in drug safety solutions worldwide, announced the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal's technology platform, LifeSphere, under the name of LifeSphere Clarity and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety. This has helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the Asia-Pacific presence in the market
- In March 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb acquired Turning Point Therapeutics for USD 76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and was anticipated to close during the third quarter of 2022. This acquisition has helped the company to increase its Asia-Pacific presence in the market.
Asia-Pacific Fibrotic Diseases Treatment Market Segmentation
The Asia-Pacific fibrotic diseases treatment market is categorized into four notable segments based on treatment, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Treatment
- Medication
- Organ Transplantation
- Oxygen Therapy
- Others
On the basis of treatment, the fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others.
Application
- Idiopathic pulmonary fibrosis
- Hepatic cirrhosis
- Renal fibrosis
- Cutaneous fibrosis
- Others
On the basis of application, the fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.
End User
- Government organization
- Hospitals
- Academic and research institutes
- Others
On the basis of end user, the fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others.
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
On the basis of distribution channel, the fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others.
Asia-Pacific Fibrotic Diseases Treatment Market Regional Analysis/Insights
The Asia-Pacific fibrotic diseases treatment market is analyzed, and market size insights and trends are provided by treatment, application, end user, and distribution channel, as referenced above.
The countries covered in the Asia-Pacific fibrotic diseases treatment report are Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, and rest of Asia-Pacific.
Japan is expected to dominate the Asia-Pacific fibrotic diseases treatment market due to increasing technological advancement in developing areas.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Fibrotic Diseases Treatment Market Share Analysis
アジア太平洋の線維性疾患治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、アジア太平洋でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、アジア太平洋の線維性疾患治療市場への企業の焦点にのみ関連しています。
アジア太平洋地域の線維性疾患治療市場のプレーヤーとしては、ベーリンガーインゲルハイムインターナショナル社、アッヴィ社、ブリストル・マイヤーズスクイブ社、ギリアド・サイエンシズ社、テバ製薬工業社、サンドスインターナショナル社などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATIENT TREATMENT SUCCESS RATE
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MERGERS AND ACQUISITIONS
7.1 LICENSING:
7.2 COMMERCIALIZATION AGREEMENTS
8 PIPELINE ANALYSIS
8.1 PHASE 1
8.2 PHASE 2
8.3 PHASE 3
9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
9.1 FDA APPROVALS
9.2 EMA APPROVALS
10 MARKET OVERVIEW
10.1 DRIVERS
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
10.2 RESTRAINTS
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
10.3 OPPORTUNITIES
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES
10.4 CHALLENGES
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT
11 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 INTEDANIB (OFEV)
11.2.2 PIRFENIDONE (ESBRIET)
11.3 ORGAN TRANSPLANTATION
11.4 OXYGEN THERAPY
11.5 OTHERS
12 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 IDIOPATHIC PULMONARY FIBROSIS
12.3 HEPATIC CIRRHOSIS
12.4 RENAL FIBROSIS
12.5 CUTANEOUS FIBROSIS
12.6 OTHERS
13 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 INDIA
15.1.4 SOUTH KOREA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 THAILAND
15.1.8 MALAYSIA
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 TAIWAN
15.1.13 REST OF ASIA-PACIFIC
16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GENENTECH, INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 SANDOZ INTERNATIONAL GMBH
18.3.1 COMPANY SNAPSHOT
18.3.2 COMPANY SHARE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ACCORD HEALTHCARE U.S.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 ABBVIE INC.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ALPINE IMMUNE SCIENCES
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 BELLBROOK LABS
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 BIOMX
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 BRISTOL-MYERS SQUIBB COMPANY
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 CAMBER PHARMACEUTICALS, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 ENVEDA
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 GILEAD SCIENCES, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 INTERCEPT PHARMACEUTICALS, INC.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 KITHER BIOTECH S.R.L.
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 PHARMAXIS LTD
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 REDX PHARMA PLC.
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 VERONA PHARMA PLC
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
表のリスト
TABLE 1 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA PACIFIC ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA PACIFIC OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA PACIFIC OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA PACIFIC HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA PACIFIC RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA PACIFIC CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 13 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 ASIA PACIFIC HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 ASIA PACIFIC SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 17 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 19 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 20 ASIA PACIFIC HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 ASIA PACIFIC RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 27 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 28 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 31 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 32 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 33 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 34 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 35 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 36 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 37 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 38 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 39 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 40 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 41 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 42 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 43 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 44 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 45 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 46 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 47 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 48 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 49 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 50 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 51 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 52 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 53 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 54 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 55 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 56 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 57 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 58 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 59 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 60 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 61 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 62 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 63 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 64 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 65 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 66 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 67 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 68 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 69 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 70 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 71 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 73 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 74 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 75 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 76 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 77 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 78 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 79 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 80 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 81 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 82 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 83 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 84 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 85 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 86 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 87 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 88 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 89 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 90 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 91 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 92 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 93 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 94 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 95 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 96 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 97 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 98 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 99 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 100 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 101 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 102 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 103 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 104 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 105 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 106 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 107 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 108 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 109 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)
TABLE 110 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME)
TABLE 111 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 112 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 113 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 114 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 115 REST OF ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
図表一覧
FIGURE 1 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030
FIGURE 13 PATIENT FLOW DIAGRAM
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET
FIGURE 15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022
FIGURE 16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND)
FIGURE 17 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030)
FIGURE 18 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE
FIGURE 19 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022
FIGURE 20 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 21 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 22 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022
FIGURE 24 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 25 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 26 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 28 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 29 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 30 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 32 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 33 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 34 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 35 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030)
FIGURE 36 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。